2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Revenue | $817M | $1B | $1.2B | $1.2B | $1.3B |
Cost of Revenue | $492M | $596M | $723M | $789M | $820M |
Gross Profit | $324M | $410M | $446M | $453M | $512M |
Gross Profit % | 40% | 41% | 38% | 36% | 38% |
R&D Expenses | $4M | $3.5M | $4.1M | $4.3M | $0 |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Net Income | $66M | $41M | $109M | $134M | $139M |
Dep. & Amort. | $20M | $23M | $26M | $27M | $28M |
Def. Tax | $8.2M | $9.4M | $12M | $11M | $8.4M |
Stock Comp. | $7.6M | $8.3M | $12M | $14M | $18M |
Chg. in WC | -$17M | -$22M | -$81M | -$18M | $19M |
2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|
Cash | $96M | $75M | $67M | $88M | $133M |
ST Investments | $0 | $0 | $0 | $0 | $0 |
Cash & ST Inv. | $96M | $75M | $67M | $88M | $133M |
Receivables | $90M | $111M | $133M | $145M | $151M |
Inventory | $59M | $97M | $125M | $117M | $142M |
Q2 net sales increased 15.2% year-over-year to $359.7M, driven by strong double-digit growth in Quest (+16.5%) and Owen (acquisition), which together now represent ~70% of net sales; Atkins declined 11.5%.
Adjusted EBITDA grew 17.6% to $68M, with net income up 10.9% to $36.7M; gross margin declined 120 bps to 36.2%, mainly due to the inclusion of Owen and inflationary pressures.
FY25 outlook reaffirmed: total reported net sales expected to increase 8.5%-10.5%, with organic growth primarily from volume; adjusted EBITDA expected to rise 4%-6%; Owen net sales guided to $140M-$150M.
Atkins is expected to decline low double digits for the year due to reduced display space and distribution losses, but these are being offset by gains for Quest and Owen; focus remains on stabilizing Atkins with innovation and targeting GLP-1 drug users.
Company expects to repay nearly all debt from the Owen acquisition by fiscal year-end, with net leverage targeted at ~0.5x; gross margin guidance incorporates higher H2 inflation and tariffs, but commodity costs are largely covered for the year.